Adverse effects of captopril in hospital outpatients with hypertension

T. Walley, P. Winstanley, D. Roberts, M. Grimmer, M. Orme and A. Breckenridge

Department of Pharmacology and Therapeutics, University of Liverpool, Ashton Street, P.O. Box 147, Liverpool L69 3BX, UK.

Summary: Hypertensive patients prescribed captopril while attending a hospital hypertension clinic were studied, to identify the benefits of the drug, its adverse effects and factors predisposing to them. One hundred and eighty two patients were followed for a mean of 18 months; 24 received captopril alone, and 158 combinations of captopril and other antihypertensive drugs, especially loop diuretics (91/158), or thiazide diuretics (57/158), or other vasodilators (57/158). The mean final dose of captopril was 67 mg/day.

Blood pressure (BP) was effectively controlled in 73% of patients (mean fall in systolic BP 29 mmHg, CI 24 to 34, P ≤ 0.001; mean fall in diastolic BP 18 mmHg, CI 16 to 20, P ≤ 0.001). Blood urea and creatinine rose slightly in all patients (urea by 0.9 mmol/l [13%], CI 0.5-1.3, P ≤ 0.001 and creatinine by 9 μmol/l [8%], CI 4-13, P ≤ 0.001). Twenty six patients were withdrawn from captopril therapy: 6 because of poor control of their blood pressure, two because it was no longer necessary and 12 (7.7%) because of extrarenal adverse effects - 10 for rashes, one each for gastric upset and impotence. Captopril was withdrawn in a further 6 patients, because of deteriorating renal function. Factors discriminating those at risk of renal dysfunction were high doses of captopril, concomitant high dose diuretic therapy and undiagnosed renovascular disease.

Introduction

Captopril and other angiotensin converting enzyme (ACE) inhibitors are at present limited to use as second line therapy in hypertension. Although undoubtedly effective, their use as first line agents is controversial because of their adverse effects, in particular, renal dysfunction. If the ACE inhibitors are to be more widely used, factors predisposing patients to the adverse effects must be better understood.

Patients referred to hospital for control of hypertension differ from those regularly managed by general practitioners alone, either because their hypertension is more difficult to control, or they have already suffered adverse effects on antihypertensive agents or they have other complicating diseases. While post-marketing surveillance in general practice has shown captopril to be an effective antihypertensive agent, few large studies have considered the use of captopril for hypertension in hospital outpatients. We studied the use of captopril in hypertensive patients attending a secondary and tertiary referral clinic, to determine its benefits, adverse effects and how these might be predicted.

Methods

From 1st January 1982 to 31st December 1987, data was collected on all patients first prescribed captopril while attending a hypertension clinic. Patients attended at 2-6 monthly intervals thereafter, until discharged back to their general practitioner’s care when their blood pressure was stable. At each patient visit, specified symptoms (e.g. rash, taste disturbance) and spontaneously volunteered symptoms were recorded in a standardized manner to assess adverse effects, especially any which required drug withdrawal. Blood pressure was recorded after the patient had rested supine for five minutes, using Korotkoff phase V for diastolic. Biochemical and haematological indices were checked before treatment and at 6 monthly intervals afterwards. Data were recorded on a personal computer. For the current report, data from the patient’s visit before captopril administration, and last visit while taking captopril were analysed. Patients on whom data was recorded at only one visit were excluded.

Statistical analysis was by Mann Whitney U test for nonparametric paired data and χ² analysis. Results are shown as mean (s.d.).
Results

One hundred and ninety eight patients were prescribed captopril during the study period. Sixteen of these were excluded because they had only attended the clinic once. From information received from their general practitioners, only one of the 16 was known to have stopped captopril because of an adverse reaction (rash). Data on 182 patients (aged 55 [11] yrs, range 20-90, 102 male and 80 female) were analysed. The mean duration of follow up was 18 (14) months. The indications for treatment with captopril were as follows: in 99, because hypertension was uncontrolled on other agents, in 19 because the patients had suffered adverse effects on other drugs despite adequate blood pressure control, and in 64 because of thiazide resistant hypertension and other complicating conditions such as peripheral vascular disease or chronic obstructive lung disease which precluded the use of some other antihypertensive agents. The mean initial dose of captopril was 64 (51) mg/day and the final dose was 67 (46) mg/day (range 12.5-300 mg/day).

Captopril was used as monotherapy in 24 patients (13%), in combination with one other drug in 90 (47%), and with two or more other drugs in 68 (37%). The most widely used combinations were captopril with the loop diuretics frusemide or bumetamide (91 patients, 50%), or captopril with thiazide diuretics (57 patients, 31%). Other vasodilators (57 patients, 31%), especially nifedipine, or beta blockers (33 patients, 18%) were used as part of triple therapy.

Efficacy

Captopril, either alone or in combination, lowered blood pressure from 183(37)/110(19) mmHg, to 154(27)/92(14) mmHg (mean difference in systolic BP 29 mmHg, 95% CI 24 to 34, P <0.001, and for diastolic BP 18 mmHg, 95% CI 16 to 20, P <0.001). However, 49 patients (27%, all on combination therapy) were considered to have inadequate control of their blood pressure (BP >160/95 mmHg) at the last clinic assessment.

Adverse effects

Effects on renal function There was a rise in both urea and creatinine during captopril therapy (Table I). This was not related to concomitant diuretic therapy, as similar rises in urea (14%) and creatinine (8%) were seen regardless of therapy with loop diuretics, thiazide diuretics or no diuretics (Table I). These rises were only statistically significant in the group of patients on diuretic therapy, but this is due to the number of patients in each group (34 on no diuretics and 91 and 57 on loop and thiazide diuretics respectively). The changes were not clinically significant, except in 6 patients (3%, all male) who had seriously deteriorating renal function and who had to discontinue captopril (Table II).

Proteinuria Eight patients developed proteinuria (more than trace on dipstick). One patient (no. 5 in Table II), developed the nephrotic syndrome (proteinuria >12 g/day). Renal biopsy showed only hypertensive nephrosclerotic changes. The nephrotic syndrome resolved when captopril was discontinued, but 2 years later this patient still had significant proteinuria (1-2 g/day). In the other patients, the proteinuria was mild and did not require cessation of treatment.

Table I  Biochemical changes in 182 patients before and after taking captopril (C) for hypertension, divided on the basis of their concurrent diuretic therapy. Mean (s.d.)

<table>
<thead>
<tr>
<th></th>
<th>C: no diuretics</th>
<th>C + loop diuretics</th>
<th>C + thiazides</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>34</td>
<td>91</td>
<td>57</td>
<td>182</td>
</tr>
<tr>
<td>Urea mmol/l</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before</td>
<td>5.5 (2.3)</td>
<td>6.8 (4.2)</td>
<td>6.0 (2.3)</td>
<td>6.4 (2.3)</td>
</tr>
<tr>
<td>After</td>
<td>5.9 (2.7)</td>
<td>7.8 (4.1)</td>
<td>6.9 (3.1)</td>
<td>7.2 (3.7)</td>
</tr>
<tr>
<td>Difference</td>
<td>0.4 (3.1)</td>
<td>1.0 (3.33)</td>
<td>0.9 (1.9)</td>
<td>0.9 (2.9)</td>
</tr>
<tr>
<td>95% CI</td>
<td>-0.4 - 1.4</td>
<td>0.3 - 1.7</td>
<td>0.3 - 1.4</td>
<td>0.5 - 1.3</td>
</tr>
<tr>
<td>P</td>
<td>&gt;0.5</td>
<td>£0.01</td>
<td>£0.005</td>
<td>£0.001</td>
</tr>
<tr>
<td>Creatinine μmol/l</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before</td>
<td>108 (32)</td>
<td>117 (52)</td>
<td>105 (34)</td>
<td>112 (45)</td>
</tr>
<tr>
<td>After</td>
<td>118 (52)</td>
<td>126 (61)</td>
<td>114 (55)</td>
<td>121 (58)</td>
</tr>
<tr>
<td>Difference</td>
<td>10 (52)</td>
<td>9 (31)</td>
<td>9 (27)</td>
<td>9 (33)</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>-7 - 27</td>
<td>2 - 16</td>
<td>2 - 16</td>
<td>4 - 13</td>
</tr>
<tr>
<td>P</td>
<td>&gt;0.1 &lt;0.5</td>
<td>£0.01</td>
<td>£0.05</td>
<td>£0.001</td>
</tr>
</tbody>
</table>
Table II Patients withdrawn from captopril therapy because of deteriorating renal function

<table>
<thead>
<tr>
<th></th>
<th>Age (years)</th>
<th>Dose (mg/day)</th>
<th>Duration (months)</th>
<th>Urea (mmol/l)</th>
<th>Creatinine (μmol/l)</th>
<th>Initial Urea</th>
<th>Final Creatinine</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>48</td>
<td>100</td>
<td>16</td>
<td>15.8</td>
<td>279</td>
<td>19.1</td>
<td>343</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>54</td>
<td>25</td>
<td>18</td>
<td>6.4</td>
<td>98</td>
<td>12.9</td>
<td>176</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>66</td>
<td>75</td>
<td>6</td>
<td>7.0</td>
<td>129</td>
<td>14.0</td>
<td>157</td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>49</td>
<td>150</td>
<td>14</td>
<td>6.1</td>
<td>116</td>
<td>10.2</td>
<td>310</td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>49</td>
<td>75</td>
<td>27</td>
<td>6.8</td>
<td>122</td>
<td>14.4</td>
<td>216</td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>57</td>
<td>150</td>
<td>48</td>
<td>5.9</td>
<td>135</td>
<td>22.4</td>
<td>202</td>
<td></td>
</tr>
</tbody>
</table>

Mean 54 s.d. 7

RAS = Renal artery stenosis. *P<0.05

Other withdrawals and adverse effects Twenty other patients stopped captopril, six because of poorly controlled hypertension and two because it was no longer thought necessary in the control of their hypertension. Twelve (6.6%, 5 female, mean age 55 [12] years) stopped captopril because of extrarenal adverse effects (10 rashes, and one each because of gastrointestinal upset and impotence). The mean captopril dose at the time of withdrawal was 97 (83) mg/day (P<0.05 compared to all patients), and the mean duration of treatment 12 (14) months. Four of the 38 patients over 65 at the time they started captopril treatment withdrew because of renal and extra renal adverse effects, an incidence of 10% compared to 5.5% in those under 65 (χ² = 0.42, not statistically significant).

One patient died from a perforated peptic ulcer while taking captopril. No patient suffered from neutropenia during captopril therapy (initial mean white cell count was 8.2 [2.3] × 10⁹/l, and the last count was 8.0 (2.3) × 10⁹/l, not significant). One patient complained of taste disturbance. No patient complained of cough.

Discussion

Previous studies of captopril in hypertensive patients found that adverse effects required drug withdrawal in 7.2–8.5%.²³ The incidence of drug withdrawal because of extrarenal adverse effects (7.7%) in the present study is therefore similar (χ² = 0.2, P>0.5).

Blood urea and serum creatinine rose after the patients studied started captopril. In most, the changes were minor and not clinically important. Since there is no control group in this study, we cannot say whether the changes in renal function are the result of captopril or other therapy, or part of the natural history of these patient's hypertension. A recent similar retrospective study found that over a mean of 5 years and regardless of the quality of blood pressure control or drug therapy, 85% of hypertensive patients had rises in serum creatinine of 3–8%.⁴ This is similar to that seen in our patients and suggests that such a rise in creatinine is part of the natural history of hypertension and not a captopril effect.

The major difference between the current and previous studies²³ is the rate of renal dysfunction requiring captopril withdrawal (3% vs 0.13%, χ² = 88.07, P ≤ 0.001). The most likely explanation for this lies in the differing populations studied, that is community versus hospital based. Rostand et al.⁴ found that 15% of similar hypertensive hospital outpatients developed gradually deteriorating renal function (serum creatinine rising by >35 μmol/l) over 5 years, but in only 1% was the deterioration clinically significant.

In two of our cases (nos. 1 and 2 in Table II), captopril was probably responsible for the deterioration in renal function. Patient 1 had glomerulo-
nephritis of unknown aetiology with deteriorating renal function, possibly due to his hypertension. Captopril was given to improve blood pressure control. Although his blood pressure fell from 180/120 to 160/96 mmHg, he still required long term dialysis. In patient 2, deterioration was probably due to diabetes mellitus and recurrent urinary tract infections. In two further cases (nos. 3 and 4), the use of captopril exposed renal artery stenosis, previously unsuspected. In the last two cases (nos. 5 and 6), no cause other than the antihypertensive medication was found to account for the changes in renal function. Patient 5 had the nephrotic syndrome; captopril has been previously associated with the nephrotic syndrome and membranous glomerulonephritis on biopsy. However, similar histological changes are found in biopsies from hypertensive patients not on captopril. Renal biopsy in the patient reported here was unhelpful.

In patient 6, the deterioration in the renal indices may be related as much to diuretics (frusemide 120 mg/day) as to captopril. The combination of diuretics and captopril is very effective in treating hypertension. But when there is diuretic-induced sodium depletion, blocking the renin-angiotensin system by captopril may severely reduce glomerular filtration rate and affect renal function. Captopril alone is less likely to cause similar problems. It is of interest therefore that 5 of the 6 patients with renal deterioration (all but no. 2) were also taking diuretics. There was no relationship between blood pressure and the risk of severe adverse renal effects, suggesting that these adverse effects were not mediated by hypotension or hypertension alone.

Some of the extrarenal adverse effects described were probably not captopril-related; for instance, captopril is not known to cause impotence. There were no complaints of unproductive cough, due partly to our failure to incorporate cough in 1981 as one of the symptoms for which specific inquiry was made in the standardized data collection.

Patients who suffered adverse effects, both renal and extrarenal, were taking higher than average doses, implying that adverse effects are dose related, but in the case of the renal adverse effects, this may also reflect the higher doses used to control hypertension in these patients.

The risk factors therefore associated with captopril-induced renal dysfunction in this study include high doses of captopril, high doses of diuretics, and undiagnosed renovascular disease. The duration of captopril therapy before the emergence of these adverse effect (6–48 months) underlines the need to monitor renal function regularly in all patients throughout their treatment with this drug.

Acknowledgement

This study was supported by Squibb UK.

References

Adverse effects of captopril in hospital outpatients with hypertension.

T. Walley, P. Winstanley, D. Roberts, M. Grimmer, M. Orme and A. Breckenridge

doi: 10.1136/pgmj.66.772.106

Updated information and services can be found at:
http://pmj.bmj.com/content/66/772/106

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/